"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

Speciality: Oncology

Description:

A warm welcome to all the medical professionals in this insightful session on "Lorlatinib Upfront: A Niche but Powerful Option For ALK+ NSCLC." This webinar, led by the distinguished Dr. Peush Bajpai, Dr. Ankur Nandan Varshney, and Dr. Vikram Singhal, delves into the cutting-edge application of lorlatinib as a frontline therapy for ALK-positive non-small cell lung cancer (NSCLC). Given its unique properties, particularly its superior central nervous system (CNS) penetration, lorlatinib presents a compelling case for upfront use in selected patients, offering enhanced intracranial efficacy and sustained progression-free survival compared to earlier generation ALK TKIs.

The discussion will highlight the pivotal role of the CROWN study, which demonstrated lorlatinib's remarkable efficacy in the first-line setting, showcasing an unprecedented improvement in progression-free survival (PFS) and a significant reduction in the risk of CNS progression. While lorlatinib offers substantial benefits, understanding its distinct toxicity profile, including metabolic changes and CNS-related adverse events, is crucial for effective patient management. Our expert panel will share practical strategies for mitigating these side effects, ensuring optimal tolerability and sustained treatment adherence.

This session promises to provide comprehensive knowledge on integrating lorlatinib into frontline management strategies for ALK-positive NSCLC, focusing on patient selection, management of adverse events, and long-term outcomes. Join us to gain valuable insights from Dr. Peush Bajpai, Dr. Ankur Nandan Varshney, and Dr. Vikram Singhal, and continue to follow Hidoc for more such interesting webinar sessions that advance your clinical practice.

See More Webinars @ Hidoc Webinars